Cara Therapeutics Inc (CARA) Raised to Hold at ValuEngine

Cara Therapeutics Inc (CARA) Raised to Hold at ValuEngine

Cara Therapeutics Inc (NASDAQ:CARA) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Friday.

A number of other equities research analysts have also recently issued reports on CARA. HC Wainwright set a $22.00 target price on shares of Cara Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 22nd. Piper Jaffray Companies reiterated an “overweight” rating and set a $23.00 target price on shares of Cara Therapeutics in a research report on Friday, March 3rd. Laidlaw increased their target price on shares of Cara Therapeutics from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, March 10th. Canaccord Genuity restated a “buy” rating and issued a $25.00 price objective on shares of Cara Therapeutics in a research report on Friday, March 10th. Finally, Cantor Fitzgerald set a $24.00 price objective on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Friday, March 10th. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $26.17.

Cara Therapeutics (NASDAQ:CARA) traded up 1.21% on Friday, reaching $17.56. 1,020,153 shares of the company’s stock traded hands. The stock’s market capitalization is $570.82 million. Cara Therapeutics has a 52-week low of $4.35 and a 52-week high of $20.90. The firm’s 50-day moving average is $16.35 and its 200 day moving average is $14.19.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by $0.08. The company had revenue of $0.91 million for the quarter, compared to analyst estimates of $0.11 million. The firm’s quarterly revenue was up 12900.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.39) EPS. Analysts forecast that Cara Therapeutics will post ($2.37) EPS for the current year.

In other Cara Therapeutics news, major shareholder Ventures Vi Lp Rho purchased 500,000 shares of the stock in a transaction dated Friday, March 31st. The stock was bought at an average price of $18.19 per share, for a total transaction of $9,095,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.70% of the stock is owned by insiders.

Several large investors have recently modified their holdings of CARA. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Cara Therapeutics by 0.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 60 shares in the last quarter. American International Group Inc. boosted its stake in shares of Cara Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,937 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 857 shares in the last quarter. Creative Planning boosted its stake in shares of Cara Therapeutics by 9.3% in the first quarter. Creative Planning now owns 14,340 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,215 shares in the last quarter. Tiedemann Wealth Management LLC boosted its stake in shares of Cara Therapeutics by 7.5% in the first quarter. Tiedemann Wealth Management LLC now owns 21,425 shares of the biopharmaceutical company’s stock valued at $394,000 after buying an additional 1,500 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares in the last quarter. Institutional investors own 43.29% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:CARA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

To view ValuEngine’s full report, visit ValuEngine’s official website.

Related posts

Leave a Comment